Replies to post #239069 on Biotech Values

[vinmantoo]

ENTA announces SARS-CoV-2_protease_inhibitor, EDP-235:

https://finance.yahoo.com/news/enanta-pharmaceuticals-announces-nomination-clinical-110000908.html

Thanks Dew. Good news for ENTA investors as now we at least get a rough timeline of the phase I safety trial to initiate. I have always felt antivirals would play a big role in defeating this pandemic. The rise of the delta variants really reinforces my view.

While the Covid-19 protease is likely an excellent target, I thought ENTA was trying to develop a multi-drug cocktail for Covid-19. Am I wrong or is another anti-viral designed to inhibit a different aspect of the viral life-cycle coming?

[DewDiligence]

ENTA new corporate slide set:

https://s22.q4cdn.com/306858242/files/doc_presentations/2021/08/Enanta-Corporate-Presentation-Final-8.5.21.pdf

[semi_infinite]

EDP-235 Any comments during CC about what remains to be done preclinically? Primate models?

[DewDiligence]

ENTA—New_preclinical_data_for EDP-235—the SaRS-CoV2 protease_inhibitor:

https://www.enanta.com/investors/news-releases/press-release/2021/Enanta-Pharmaceuticals-Presents-New-Data-for-EDP-235-its-Lead-Oral-Protease-Inhibitor-Designed-for-the-Treatment-of-COVID-19-at-the-ISIRVWHO-Virtual-Conference-2021/default.aspx